Child; Follow-Up Studies; Humans; Neoplasms/therapy; Neoplasms, Second Primary; Referral and Consultation; Survivors; Pediatric cancer; Sequellae; Long; term follow; up
Résumé :
[en] During the past 50 years, the mortality due to childhood cancers decreased dramatically thanks to improvements in supportive care and the use of multimodal approaches. In this context, the long-term follow up after childhood cancer has become a main concern for pediatric oncologists. The SALTO programme was developed in 2012 at the CHR Citadelle in Liège in order to organize a multidisciplinary long-term follow-up for the patients previously treated in our department for a childhood cancer. The aim of the present study was to review, for the most frequent childhood cancers, the long-term sequellae and the second cancers developed by the patients participating to the SALTO programme in order to define the follow-up needed. Our data confirm the importance of a multidisciplinary long-term follow-up, based on the treatments received and following international guidelines.
Disciplines :
Pédiatrie Oncologie
Auteur, co-auteur :
FOHN, Anaîs ; Centre Hospitalier Universitaire de Liège - CHU > Département de Pédiatrie > Service de pédiatrie
Quenon, C.; CHU Liège > SALTO
Jacquemin, C.; Centre Hospitalier Régional de la Citadelle (Liège) - CHR CITADELLE > SALTO
David, Bianca-Andreea ; Centre Hospitalier Universitaire de Liège - CHU > Département de Pédiatrie > Service de pédiatrie
Belgian Cancer Registry. Cancer in children and adolescent in Belgium 2004-2006. 2019.
Armstrong GT, Chen Y, Yasui Y, et al. Reduction in late mortality among five-year survivors of childhood cancer. N Engl J Med 2016;374:833-42.
Michel G, Mulder RL, van der Pal HJ, et al. Evidence-based recommendations for the organization of long-term follow-up care for childhood and adolescent cancer survivors: a report from the PanCareSurFup Guidelines Working Group. J Cancer Surviv 2019;13:759-72.
Schündeln MM, Hauffa PK, Munteanu M, et al. Prevalence of osteopathologies in children and adolescents after diagnosis of acute lymphoblastic leukemia. Front Pediatr 2020;8:1-10.
Vetsch J, Wakefield CE, Robertson EG, et al. Health-related quality of life of survivors of childhood acute lymphoblastic leukemia: a systematic review. Qual Life Res 2018;27:1431-43.
Mulrooney DA, Hyun G, Ness KK, et al. The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study. Lancet Haematol 2019;6:e306-e16.
Piette C, Suciu S, Bertrand Y, et al. Prophylactic CNS therapy (with or without radiation therapy) in medium-high risk acute lymphoblastic leukemia (ALL) children: long-term outcome evaluation of the randomized BFM-oriented trial 58832 (period 1983-1989) of the EORTC Children Leukemia Group. Blood 2016;128:2775.
Turner CD, Rey-Casserly C, Liptak CC, Chordas C. Late effects of therapy for pediatric brain tumor survivors. J Child Neurol 2009;24:1455-63.
Alemani M, Velasco R, Simo M, Jordi B. Late effects of cancer treatment: consequences for long-term brain cancer survivors. Neuro-Oncol Pract 2021;8:18-30.
Gurney JG, Kadan-Lottick NS, Packer RJ, et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors: Childhood cancer survivor study. Cancer 2003;97:663-73.
Vinchon M, Baroncini M, Leblond P, Delestret I. Morbidity and tumor-related mortality among adult survivors of pediatric brain tumors: A review. Childs Nerv Syst 2011;27:697-704.
Sala A, Talsma D, Webber C, et al. Bone mineral status after treatment of malignant lymphoma in childhood and adolescence: Original article. Eur J Cancer Care (Engl) 2007;16:373-9.
Dorffel W, Riepenhausen M, Lüders H, Brämswig J. Late effects following treatment of hodgkin lymphoma during childhood and adolescenceresults of the hodgkin lymphoma late effects research project. Klin Paediatr 2016;228:286-93.
Friedman D, Constine LS. Late effects of treatment for Hodgkin lymphoma. J Natl Compr Canc Netw 2006;4:249-57.
Van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines. Blood 2017;129:2257-65.
Laverdiére C, Liu Q, Yasui Y, et al. Long-term outcomes in survivors of neuroblastoma: A report from the childhood cancer survivor study. J Natl Cancer Inst 2009;101:1131-40.
Friedman D, Henderson T. Late effects and survivorship issues in patients with neuroblastoma. Children (Basel) 2018;5:107.
Van Santen HM, De Kraker J, Vulsma T. Endocrine late effects from multi-modality treatment of neuroblastoma. Eur J Cancer 2005;41:1767-74.
Neu MA, Russo A, Wingerter A, et al. Prospective analysis of long-term renal function in survivors of childhood Wilms tumor. Pediatr Nephrol 2017;32:1915-25.
Wright KD, Green DM, Daw NC. Late effects of treatment for Wilms tumor. Pediatr Hematol Oncol 2009;26:407-13.
Hamilton SN, Carlson R, Hasan H, et al. Long-term outcomes and complications in pediatric ewing sarcoma. Am J Clin Oncol 2017;40:423-8.
Berendsen AJ, Groot Nibbelink A, Blaauwbroek R, et al. Second cancers after childhood cancer-GPs beware! Scand J Prim Health Care 2013;31:147-52.
Turcotte LM, Liu Q, Yasui Y, et al. Temporal trends in treatment and subsequent neoplasm risk among five-year survivors of childhood cancer, 1970-2015 HHS Public Access. JAMA 2017;317:814-24.
Scholz-Kreisel P, Kaatsch P, Spix C, et al. Second malignancies following childhood cancer treatment in Germany from 1980 to 2014-a registry-based analysis. Dtsch Arztebl Int 2018;115:385-92.
Haupt R, Essiaf S, Dellacasa C, et al. The ‘Survivorship Passport’ for childhood cancer survivors. Eur J Cancer 2018;102:69-81.
Quenon C. Suivi à long terme des adultes atteints d’un cancer dans l’enfance: outil d’aide pour les médecins généralistes. Université de Liège. 2020.
